A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Poly ICLC (Primary)
- Indications Colon cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Jan 2021.
- 12 Jan 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2020.
- 12 Jan 2018 Status changed from not yet recruiting to recruiting.